Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108

1.

Pharmacokinetics and pharmacodynamics of insulin aspart in patients with type 2 diabetes: assessment using a meal tolerance test under clinical conditions.

Ando H, Kurita S, Shimizu A, Kato K, Ishikura K, Taji K, Uno M, Takeshita Y, Misu H, Fujimura A, Kaneko S, Takamura T.

Clin Exp Pharmacol Physiol. 2012 Jun;39(6):528-34. doi: 10.1111/j.1440-1681.2012.05708.x.

PMID:
22642657
2.

Efficacy comparison between preprandial and postprandial insulin aspart administration with dose adjustment for unpredictable meal size.

Jovanovic L, Giammattei J, Acquistapace M, Bornstein K, Sommermann E, Pettitt DJ.

Clin Ther. 2004 Sep;26(9):1492-7.

PMID:
15531011
3.

Insulin aspart improves meal time glycaemic control in patients with Type 2 diabetes: a randomized, stratified, double-blind and cross-over trial.

Perriello G, Pampanelli S, Porcellati F, Avogaro A, Bosi E, Petrella G, Squatrito S, Furneri S, Marra G, Vitali L, Previti M, Cucinotta D.

Diabet Med. 2005 May;22(5):606-11.

PMID:
15842516
4.

Improved postprandial glycemic control with biphasic insulin aspart relative to biphasic insulin lispro and biphasic human insulin in patients with type 2 diabetes.

Hermansen K, Colombo M, Storgaard H, ØStergaard A, Kølendorf K, Madsbad S.

Diabetes Care. 2002 May;25(5):883-8.

PMID:
11978685
5.

The pharmacokinetics and pharmacodynamics of rapid-acting insulin analogues and their clinical consequences.

Home PD.

Diabetes Obes Metab. 2012 Sep;14(9):780-8. doi: 10.1111/j.1463-1326.2012.01580.x. Epub 2012 Mar 9. Review.

PMID:
22321739
6.
7.
8.

A comparison of pharmacokinetics and pharmacodynamics of insulin aspart, biphasic insulin aspart 70, biphasic insulin aspart 50, and human insulin: a randomized, quadruple crossover study.

Ma Z, Parkner T, Frystyk J, Laursen T, Lauritzen T, Christiansen JS.

Diabetes Technol Ther. 2012 Jul;14(7):589-95. doi: 10.1089/dia.2011.0299. Epub 2012 Apr 20.

PMID:
22519735
9.
10.

Postprandial glycemic control with biphasic insulin aspart in patients with type 1 diabetes.

Hermansen K, Vaaler S, Madsbad S, Dalgaard M, Zander M, Begtrup K, Soendergaard K.

Metabolism. 2002 Jul;51(7):896-900.

PMID:
12077738
11.

A direct comparison of insulin aspart and insulin lispro in patients with type 1 diabetes.

Plank J, Wutte A, Brunner G, Siebenhofer A, Semlitsch B, Sommer R, Hirschberger S, Pieber TR.

Diabetes Care. 2002 Nov;25(11):2053-7.

PMID:
12401756
12.

The post-prandial state in Type 2 diabetes and endothelial dysfunction: effects of insulin aspart.

Ceriello A, Cavarape A, Martinelli L, Da Ros R, Marra G, Quagliaro L, Piconi L, Assaloni R, Motz E.

Diabet Med. 2004 Feb;21(2):171-5.

PMID:
14984453
13.

Improved postprandial glycemic control with Humalog Mix75/25 after a standard test meal in patients with type 2 diabetes mellitus.

Malone JK, Woodworth JR, Arora V, Yang H, Campaigne BN, Hallé JP, Yale JF, Grossman LD.

Clin Ther. 2000 Feb;22(2):222-30.

PMID:
10743981
14.

Optimal dose and timing of insulin Aspart to mimic first phase insulin response in patients with recently onset type 2 diabetes.

Gredal C, Rosenfalck A, Dejgaard A, Hilsted J.

Diabetes Res Clin Pract. 2008 May;80(2):293-8. doi: 10.1016/j.diabres.2007.12.023. Epub 2008 Mar 4.

PMID:
18304675
15.

Differences in pharmacokinetics and pharmacodynamics of insulin lispro and aspart in healthy volunteers.

von Mach MA, Brinkmann C, Hansen T, Weilemann LS, Beyer J.

Exp Clin Endocrinol Diabetes. 2002 Nov;110(8):416-9.

PMID:
12518253
16.

Faster-acting insulin aspart: earlier onset of appearance and greater early pharmacokinetic and pharmacodynamic effects than insulin aspart.

Heise T, Hövelmann U, Brøndsted L, Adrian CL, Nosek L, Haahr H.

Diabetes Obes Metab. 2015 Jul;17(7):682-8. doi: 10.1111/dom.12468. Epub 2015 May 8.

17.

Therapeutic efficacy of mitiglinide combined with once daily insulin glargine after switching from multiple daily insulin regimen of aspart insulin and glargine in patients with type 2 diabetes mellitus.

Yoshihara T, Kumashiro N, Kanazawa Y, Mita T, Sakurai Y, Kawai J, Abe M, Motojima K, Hara K, Yamazaki Y, Kanazawa A, Miwa S, Sato F, Kanno R, Shimizu T, Sakai K, Uchino H, Watada H, Tanaka Y, Kawamori R, Hirose T.

Endocr J. 2006 Feb;53(1):67-72.

18.
19.
20.

Effects of mealtime insulin aspart and bedtime neutral protamine Hagedorn insulin on postprandial coagulation and fibrinolysis in patients with type 2 diabetes.

Bladbjerg EM, Henriksen JE, Akram S, Gram J.

Diabetes Obes Metab. 2012 May;14(5):447-53. doi: 10.1111/j.1463-1326.2011.01547.x. Epub 2012 Jan 6.

PMID:
22151836

Supplemental Content

Support Center